deltatrials
Terminated PHASE2 INTERVENTIONAL NCT00100711

Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Refractory or Relapsed Disease

Sponsor: Pharmacyclics LLC.

Conditions Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
Interventions Motexafin Gadolinium
Updated 8 times since 2017 Last updated: May 7, 2014 Started: Oct 31, 2004 Primary completion: Feb 28, 2010
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

A PHASE2 clinical study on Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, this trial is terminated or withdrawn. The trial is conducted by Pharmacyclics LLC. and has accumulated 8 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshotTerminated~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 19 months · monthly snapshotTerminated~Jan 2026 – present · 3 months · monthly snapshotTerminated

Change History

8 versions recorded

  1. Jan 2026 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Present [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Apr 2022 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Jan 2021 — Apr 2022 [monthly]

    Terminated PHASE2

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  2. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pharmacyclics LLC.
Data source: Pharmacyclics LLC.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations